New combo pill shows promise for HIV patients fighting TB
NCT ID NCT04734652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new HIV medication (Biktarvy) taken twice daily in 122 adults who also have drug-sensitive tuberculosis (TB) and are on standard TB treatment. The goal was to see if the new pill can control HIV just as well as the current standard treatment. The study measured how many people had undetectable HIV levels after 24 and 48 weeks, while also monitoring safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CAPRISA Springfield Clinical Research Site
Durban, KwaZulu-Natal, 4001, South Africa